← Back to Search

Other

Cooling Helmets for Concussion (ColdCon Trial)

N/A
Recruiting
Research Sponsored by Spectrum Health - Lakeland
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 72 hours
Awards & highlights
No Placebo-Only Group

Summary

This trial tests if a cooling helmet can help adults with mild traumatic brain injuries recover faster. The helmet cools the head and neck to lower brain temperature, potentially reducing symptoms. Patients will be monitored for symptom severity and side effects over a few days. Cooling has been studied as a method to reduce symptoms and pathological changes after concussive injuries.

Who is the study for?
This trial is for individuals aged 19-65 who've had a mild traumatic brain injury with symptoms like headaches within the first day of injury. They must have a Glasgow Coma Scale score over 13 and be able to consent. It's not for pregnant women, those with certain medical conditions, or severe migraines.
What is being tested?
The study tests if cooling helmets (Catalyst Cryohelmet) can help reduce concussion symptoms after a head injury. Participants will use the helmet and their symptoms will be tracked using interviews over three days to see if there's improvement.
What are the potential side effects?
Potential side effects may include discomfort from cold temperatures, skin irritation where the helmet contacts the head, and possible worsening of pre-existing conditions sensitive to cold exposure.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~72 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 72 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Post-Concussion Symptom Severity Score Index case report form
Secondary study objectives
Pharmaceutical Preparations
Pharmaceutical Preparations
Patient Returns to Baseline Function of 0 by 1 hour survey
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Catalyst Cryohelmet intervention with symptomatic careExperimental Treatment1 Intervention
The treatment arm will receive symptomatic care (acetaminophen 1000mg and ondansetron 4mg) along with 30 minutes of head-neck cooling in the emergency department while being monitored for side effects.
Group II: Control: symptomatic care armActive Control1 Intervention
The control arm will receive symptomatic care (acetaminophen 1000mg and ondansetron 4mg). They will not wear any helmets.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Traumatic Brain Injury (TBI) include symptomatic care, rest, and gradual return to activity. Head and neck cooling, a treatment being studied, aims to reduce brain temperature, which can help mitigate secondary injury processes such as inflammation and metabolic dysfunction. This cooling effect can decrease the intensity and duration of symptoms, prevent further injury, and promote recovery. Other standard interventions focus on maintaining adequate cerebral perfusion and oxygenation, controlling intracranial pressure, and preventing complications like seizures. These treatments are crucial for improving neurological outcomes and enhancing the overall recovery process for TBI patients.
The evidence for hypothermia as a neuroprotectant in traumatic brain injury.

Find a Location

Who is running the clinical trial?

Spectrum Health - LakelandLead Sponsor
13 Previous Clinical Trials
1,309 Total Patients Enrolled

Media Library

Catalyst Cryohelmet (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05473897 — N/A
Traumatic Brain Injury Clinical Trial 2023: Catalyst Cryohelmet Highlights & Side Effects. Trial Name: NCT05473897 — N/A
Catalyst Cryohelmet (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05473897 — N/A
Traumatic Brain Injury Research Study Groups: Control: symptomatic care arm, Catalyst Cryohelmet intervention with symptomatic care
~12 spots leftby Nov 2025